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Background: Although there have been case reports of hypothalamic–pituitary–adrenal (HPA) axis suppression in patients with cystic ﬁbrosis
(CF) caused by the combination of oral itraconazole and inhaled ﬂuticasone, to date no study has assessed the incidence of this potentially serious
side effect.
Methods: Synacthen tests were conducted on all patients with CF receiving itraconazole and inhaled ﬂuticasone and an equal number of patients
with CF receiving inhaled ﬂuticasone but not itraconazole. Itraconazole levels were measured in patients receiving the therapy.
Results: Twelve patients receiving itraconazole and ﬂuticasone underwent synacthen tests. All 12 had abnormal synacthen test results and 10/12
(83%) had HPA axis suppression. Two patients had severe HPA axis suppression with a peak cortisol b75 nmol/L and further 3 patients had
moderately severe suppression with a peak cortisol b250 nmol/L. In contrast, only 2/12 on ﬂuticasone alone had HPA axis suppression (both
mild). The median (range) basal cortisol levels were signiﬁcantly lower in those patients receiving itraconazole and inhaled ﬂuticasone compared
to those on ﬂuticasone alone (219(22–508)nmol/L v 348(41–738)nnmol/L, p=0.02), similar results were seen for peak cortisol levels
(404(59–706)nmol/L v 672(432–1178)nmol/L, pb0.001) and cortisol rise (179(37–240)nmol/L v 368(210–539)nmol/L, pb0.001). The median
(range) itraconazole level was 5.5(1.7–14.7)mg/L. Neither itraconazole levels nor ﬂuticasone dose correlated with the degree of adrenal
suppression.
Conclusions: In this study, all patients receiving itraconazole and inhaled ﬂuticasone had abnormal synacthen test results. The incidence of HPA
axis suppression with this treatment combination appears to be higher than that previously reported with itraconazole and inhaled budesonide.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Adrenal suppression; Aspergillus lung disease; Cystic ﬁbrosis; Fluticasone; Inhaled corticosteroids; Itraconazole1. Introduction
There have been a number of case reports of hypothalamic–
pituitary-axis (HPA) suppression in patients with cystic fibrosis
(CF) who are receiving both oral itraconazole and inhaled
corticosteroid (ICS) [1–3]. This suppression is thought to be
caused by itraconazole inhibiting the cytochrome P450
dependent CYP3A4 pathway involved in metabolising some
synthetic glucocorticoids [4]. This leads to increased cortico-⁎ Corresponding author. Tel.: +44 7815 205459.
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http://dx.doi.org/10.1016/j.jcf.2012.10.007lishedsteroid levels, which negatively feedback on the HPA axis. In
addition to adrenal suppression, some patients develop signs
and symptoms of Cushing's syndrome due to the elevated
corticosteroid levels [3]. In most of the reported cases the
patients were receiving oral itraconazole and inhaled budesonide,
a subsequent study found that 11/25 (44%) patients with CF on
this treatment combination had HPA axis suppression [5]. To our
knowledge, no previous study has assessed the incidence of HPA
axis suppression in patients with CF treated with oral itraconazole
and inhaled fluticasone.
At the Manchester Adult CF Unit, the proportion of
patients prescribed inhaled corticosteroid (ICS) for bronchialby Elsevier B.V. All rights reserved.
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Over the same period the use of itraconazole has steadily increased
meaning that more patients are potentially at risk of HPA axis
suppression caused by the combination of ICS and itraconazole. A
number of patients with cystic fibrosis related diabetes (CFRD) on
oral itraconazole and inhaled fluticasone presented to our unit with
hypoglycaemic episodes or poor glycaemic control. This leads us
to hypothesize that the incidence of HPA axis suppression in
patients with CF receiving itraconazole and inhaled fluticasone is
higher than the previously published incidence in CF patients
receiving itraconazole and inhaled budesonide.
2. Methods
Patients attending our unit who were prescribed both oral
itraconazole and inhaled fluticasone were identified using
pharmacy records and patient notes. Patients were approached
and if informed consent was granted, a synacthen test was
arranged. An equal number of patients with CF, receiving inhaled
fluticasone but not itraconazole also underwent synacthen tests.
These patients were identified at consecutive annual reviews and
recruitment stopped when we had recruited equal numbers to the
itraconazole and inhaled fluticasone group. In both groups,
patients were excluded if they had taken any exogenous source of
corticosteroids other than inhaled fluticasone in the last
12 months. Patients were also excluded if their general practice
records documented their pick-up rate for either item to be b75%
over the last 12 months or if they reported their adherence as
variable or poor. Short synacthen tests were undertaken in
accordance to a standard protocol at a time of clinical stability.
Plasma cortisol levels were taken before (time 0) as well as 30
and 60 min after an intramuscular injection of 250 mcg
tetracosactide (Synacthen®). All patients withheld the use of
ICS for 3 days prior to the test. A normal response was defined as
a cortisol increase N200 nmol/L to a peak value N570 nmol/L. A
plasma itraconazole level (measured routinely at our unit) was
also taken at time 0 (target concentration: 5–17 mg/L).
3. Results
3.1. Itraconazole and inhaled fluticasone
We identified 12 patients (11 male) prescribed itraconazole
and inhaled fluticasone. The median age was 25.8 (range 18.6–
44.7) years. All had been on inhaled fluticasone for N12 months;Table 1
Summary of patients' age, daily dose of ICS, itraconazole levels and synacthen test
Age Fluticasone dose
(mcg/day)
Itracon
(mg/L
ICS and itraconazole
(n=12)
25.8 (18.6-44.7) 500 (500–1000) 5.5 (1.
ICS alone
(n=12)
29.8 (18.5-43.5) 1000 (500–1000) N/A
p value 0.33 0.10
All results are given as median (range). ICS: inhaled corticosteroid, N/A: not applic
p values are generated using the Mann Whitney U Test.8 patients were receiving 500 mcg per day and 4 patients
were receiving 1000 mcg per day. The dose of itraconazole
was 200 mg BD (7 liquid preparation and 5 capsules) for all
12 patients. The median duration of itraconazole therapy was
1.4 (range 0.4 to 3.6) years. The indication for the initiation
of itraconazole therapy had been allergic bronchopulmonary
aspergillosis (ABPA) in 10 patients and Aspergillus bron-
chitis in 2 patients. Synacthen test were abnormal in all 12
patients and there was HPA axis suppression in 10/12 (83%)
of patients (Table 1).Two patients had high baseline cortisol
levels (414 and 508 nmol/L) and although they did not
achieved a rise in cortisol of N200 nmol/L their peak cortisol
was b570 nmol/L. Despite their abnormal synacthen test
results, we did not define them as having HPA axis
suppression. Two patients had severe HPA axis suppression
with a peak cortisol b75 nmol/L and a further 3 patients had
moderately severe suppression with a peak cortisol b250 nmol/L.
Five patients had subtherapeutic (b5 mg/L) itraconazole levels and
no-one had supratherapeutic (N15 mg/L) levels. The degree of
HPA axis suppression was not correlated to the itraconazole level
or the inhaled fluticasone dose.3.2. Inhaled fluticasone and no itraconazole
Data were also collected on 12 patients (6 male) receiving
inhaled fluticasone but not itraconazole. Their median age was
29.8 (range 18.5–43.5)years. All 12 patients had been on
inhaled fluticasone for N12 months; 3 patients were receiving
500 mcg per day and 9 patients were receiving 1000 mcg/day.
A cortisol rise of N200 nmol/L was seen in all 12 patients but 2
did not achieve a peak cortisol of N570 nmol/L (one achieved
432 nmol/L and the other 559 nmol/L).
4. Discussion
In this study, all patients receiving itraconazole and inhaled
fluticasone had abnormal synacthen test results and 10/12
(83%) had HPA axis suppression. The severity of this
suppression varied from mild with limited clinical significance,
to severe and potentially life threatening. One of the patients
with severe HPA axis suppression had clinical evidence of
Cushing's syndrome secondary to the high ICS concentrations.
This 83% incidence of HPA axis suppression for patients with
CF receiving itraconazole and inhaled fluticasone is higher thanresults.
azole level
)
Synacthen test result (nmol/L)
Basal cortisol Peak cortisol Cortisol rise
7–14.7) 219 (22–508) 404 (59–706) 179 (37–240)
348 (41–738) 672 (432–1178) 368 (210–539)
0.02 b0.001 b0.001
able.
401F.J. Gilchrist et al. / Journal of Cystic Fibrosis 12 (2013) 399–402the reported incidence of 44% found in patients receiving
itraconazole and inhaled budesonide [5]. Mild HPA axis
suppression was found in 2 patients (17%) receiving ICS
without itraconazole, an association that has been previously
described in asthmatic patients [6]. The systemic bioactivity of
inhaled fluticasone and budesonide relate to pulmonary
vascular absorption. As inhaled fluticasone has been shown to
cause more adrenal suppression than an equivalent dose of
inhaled budesonide in asthmatic patients [6] it is perhaps
unsurprising that it also causes more adrenal suppression when
in combination with itraconazole.
The two groups were well matched for age. We believe that
the high number of males in the itraconazole and inhaled
fluticasone group is related to the small sample size and do not
think that there is a true sex difference; a larger study is needed
to definitively answer this question. The degree of adrenal
suppression did not correlate with the inhaled fluticasone dose
and in our study there was a non-significant trend for those on
itraconazole and inhaled fluticasone to be on a lower
fluticasone dose than those on inhaled fluticasone alone. This
suggests that the incidence of HPA axis suppression was not
underestimated in the inhaled fluticasone alone group and that
the addition of itraconazole has a significant effect on systemic
steroid levels. There was also no direct correlation between the
degree of HPA axis suppression and the plasma itraconazole
level. It is well recognised that itraconazole absorption is
variable [7] and this rather than variable adherence, is likely to
be the explanation for the wide range of itraconazole levels.
HPA axis suppression is a particular concern in patients with
CFRD as it may result in insulin requirements increasing or
decreasing. The elevated corticosteroid levels increase gluconeo-
genesis in the liver which can raise plasma glucose levels. In
contrast, patients with adrenal insufficiency secondary to HPA
axis suppression may also be at risk of hypoglycaemia, especially
in situations which initiate a stress response such as infection or
decrease adherence with treatment. Hypoglycaemic episodes in
such patients may be severe and potentially life threatening due to
their inability to mount a normal adrenal response. Care therefore
has to be taken when reducing or stopping ICS or itraconazole in
patients with CFRD. The elevated corticosteroid levels seen in
patients treated with itraconazole and ICS also have the potential
to have a detrimental effect on patients bone mineral density and
the growth.
The use of ICS in CF is controversial and despite a Cochrane
review concluding that at present there is no evidence of benefit
[8], databases of annual review returns have recorded the use of
ICS amongst CF patients in the UK to be as high as 36% [9].
The continued high use of ICS in CF patients and the increasing
rates of itraconazole prescription mean that more patients are at
risk of iatrogenic HPA axis suppression. The most appropriate
management for patients with confirmed HPA axis suppression
is not fully understood but is dependent on the degree of
suppression. In the majority of patients, reducing or stopping
one or both of itraconazole and ICS is likely to be the only
management required. A previous study has shown that it is
safe to consider stopping ICS in patients with CF [10]. The use
of itraconazole should be reviewed regularly and discontinuedif the treatment targets have been reached or if treatment has
failed.
In addition to HPA axis suppression, patients at our unit
have encountered gastrointestinal symptoms, oedema and
severe lethargy as side effects of itraconazole and its ability to
cause hepatotoxicity is well documented [11]. Ten of the
patients receiving itraconazole and inhaled fluticasone had their
treatment changed as a result of the synacthen test: 5 had ICS
reduced, stopped or changed, 2 had itraconazole reduced or
stopped and 3 had both reduced or stopped. One patient had
their ICS changed from fluticasone to ciclesonide which is
believed to have fewer systemic side effects [12], although
there is a paucity of data regarding its use in patients with CF.
In addition to stopping ICS, the 2 patients with severe HPA axis
suppression were also commenced on hydrocortisone therapy
replacement. Approximately 6 months after replacement ther-
apy was started, the degree of HPA axis suppression was
reassessed in both patients. Although there was some improve-
ment, a significant degree of suppression remained. This is in
keeping with the previous study in patients with CF receiving
itraconazole and inhaled budesonide in which the majority of
patients still had some degree of HPA axis suppression
9–10 months after initial diagnosis and appropriate changes to
the treatment regimen [5]. As far as we are aware, no study has
followed up patients beyond 10 months.
In summary this article highlights the risk of HPA axis
suppression in patients treated with itraconazole and inhaled
fluticasone. The degree of suppression varies but is potentially life
threatening in a minority of patients. The incidence of HPA axis
suppression with this treatment combination is higher than
previous studies of CF patients prescribed itraconazole and
inhaled budesonide [5]. CF physicians need to be aware of this
serious iatrogenic effect and decrease patient risk by regularly
reviewing the use of itraconazole and ICS, stopping them when
possible. If this combination of treatment is unavoidable then
consideration should be given to reducing the dose of ICS and
monitoring for HPA axis suppression with regular synacthen tests.
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